AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20739431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib after high-dose melphalan
Number of subjects: 39
Study 20739431 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib before high-dose melphalan
Number of subjects: 39
Study 18188757 — intervention group
Group type: EXPERIMENTAL
Intervention: Night smoking
Number of subjects: 691
Study 18188757 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy overnight
Number of subjects: 691
Study 18188757 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatments that improve sleep quality
Number of subjects: 691
Study 15745651 — intervention group
Group type: EXPERIMENTAL
Intervention: COG‐AFF (mismatched to affective)
Number of subjects: 100
Study 15745651 — intervention group
Group type: EXPERIMENTAL
Intervention: AFF‐COG (mismatched to cognitive)
Number of subjects: 100
Study 15745651 — intervention group
Group type: EXPERIMENTAL
Intervention: COG‐COG (matched cognitive)
Number of subjects: 100
Study 15745651 — intervention group
Group type: EXPERIMENTAL
Intervention: AFF‐AFF (matched affective)
Number of subjects: 100
Study 12532389 — intervention group
Group type: EXPERIMENTAL
Intervention: Submicron oil-in-water (o/w) emulsion
Number of subjects: 0
Study 12532389 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisolid water-in-oil (w/o) emulsion
Number of subjects: 0
Study 12532389 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min application time
Number of subjects: 0
Study 12532389 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 min application time
Number of subjects: 0
Study 12532389 — intervention group
Group type: EXPERIMENTAL
Intervention: 240 min application time
Number of subjects: 0
Study 10723849 — intervention group
Group type: EXPERIMENTAL
Intervention: CMCA intervention
Number of subjects: 15
Study 10723849 — intervention group
Group type: COMPARATOR
Intervention: Control group (age 21 and over)
Number of subjects: 15
Study 9196769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefloquine 250 mg weekly
Number of subjects: 624
Study 9196769 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine 300 mg weekly and proguanil 200 mg daily
Number of subjects: 624
Study 1330396 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (solution, fasted)
Number of subjects: 12
Study 1330396 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (capsule with food)
Number of subjects: 12
Study 1330396 — intervention group
Group type: COMPARATOR
Intervention: Treatment C (capsule without food)
Number of subjects: 12
Study 1330396 — intervention group
Group type: EXPERIMENTAL
Intervention: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment A
Number of subjects: 12
Study 1330396 — intervention group
Group type: EXPERIMENTAL
Intervention: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment B
Number of subjects: 12
Study 1330396 — intervention group
Group type: COMPARATOR
Intervention: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment C
Number of subjects: 12
Study 4068909 — intervention group
Group type: COMPARATOR
Intervention: Moderate fat formula diet (32% energy as corn oil)
Number of subjects: 0
Study 4068909 — intervention group
Group type: COMPARATOR
Intervention: Low fat formula diet (9% fat)
Number of subjects: 0
Study 4068909 — intervention group
Group type: COMPARATOR
Intervention: Very low fat formula diet (1-3% fat)
Number of subjects: 0
Study 4068909 — intervention group
Group type: COMPARATOR
Intervention: Low and very low fat formulas (ingested for three weeks)
Number of subjects: 0
Study 4068909 — intervention group
Group type: COMPARATOR
Intervention: Moderate fat formula diet (high P/S ratio)
Number of subjects: 0
Study 31342474 — intervention group
Group type: EXPERIMENTAL
Intervention: 19 G Franseen-tip core biopsy needle (FNB)
Number of subjects: 40
Study 31342474 — intervention group
Group type: COMPARATOR
Intervention: 19 G aspiration needle (FNA)
Number of subjects: 40
Study 29852863 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (300 mg daily)
Number of subjects: 160
Study 29852863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 160
Study 26513023 — intervention group
Group type: EXPERIMENTAL
Intervention: eDST (electronic decision support tool)
Number of subjects: 259
Study 26513023 — intervention group
Group type: COMPARATOR
Intervention: Control group (using any resource in addition to the app)
Number of subjects: 259
Study 26513023 — intervention group
Group type: EXPERIMENTAL
Intervention: eDST
Number of subjects: 259
Study 26513023 — intervention group
Group type: COMPARATOR
Intervention: Control group (using cognitive aids)
Number of subjects: 259
Study 26513023 — intervention group
Group type: EXPERIMENTAL
Intervention: eDST and Control
Number of subjects: 259
Study 24898101 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral antibiotic switch (group A)
Number of subjects: 59
Study 24898101 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous antibiotics (group B)
Number of subjects: 59
Study 22940436 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K6 cigarette (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Number of subjects: 160
Study 22940436 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K3 cigarette (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Number of subjects: 160
Study 22940436 — intervention group
Group type: EXPERIMENTAL
Intervention: Philip Morris One cigarettes (1mg tar, 0.1mg nicotine, and 2.0mg CO)
Number of subjects: 160
Study 22940436 — intervention group
Group type: EXPERIMENTAL
Intervention: No smoking
Number of subjects: 160
Study 22940436 — intervention group
Group type: COMPARATOR
Intervention: Marlboro cigarettes (6 mg tar, 0.5mg nicotine, and 7.0mg CO)
Number of subjects: 160
Study 19965667 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo SCT)
Number of subjects: 84
Study 18294729 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (3 L/minute)
Number of subjects: 110
Study 18294729 — intervention group
Group type: COMPARATOR
Intervention: Compressed air (room air)
Number of subjects: 110
Study 15839920 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 7.5 mg
Number of subjects: 1059
Study 15839920 — intervention group
Group type: EXPERIMENTAL
Intervention: Darifenacin 15 mg
Number of subjects: 1059
Study 15839920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1059
Study 12691375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariporide 120 mg
Number of subjects: 11590
Study 12691375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11590
Study 12691375 — intervention group
Group type: EXPERIMENTAL
Intervention: CK-MB values >10 times the upper limit of normal
Number of subjects: 11590
Study 11798671 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (12.5mg three times daily)
Number of subjects: 1376
Study 11798671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1376
Study 8923833 — intervention group
Group type: EXPERIMENTAL
Intervention: hCRH (0.4 microgram/kg) and NAL (65 micrograms/kg)
Number of subjects: 11
Study 8923833 — intervention group
Group type: EXPERIMENTAL
Intervention: MET pretreatment plus CRH/NAL
Number of subjects: 11
Study 8923833 — intervention group
Group type: EXPERIMENTAL
Intervention: NAL
Number of subjects: 11
Study 8923833 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment plus CRH/NAL stimulation
Number of subjects: 11
Study 8923833 — intervention group
Group type: COMPARATOR
Intervention: MET alone
Number of subjects: 11
Study 1746790 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine elixir 3 mg/kg via nasogastric tube every 12 hours
Number of subjects: 36
Study 1746790 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) ranitidine 1 mg/kg every 8 hours
Number of subjects: 36
Study 6700849 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-g preoperative dose of cefoxitin
Number of subjects: 112
Study 6700849 — intervention group
Group type: COMPARATOR
Intervention: Three 2-g doses of cefoxitin over 12 hours
Number of subjects: 112
Study 29948596 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential oil treatment applied by self-massage on the suprapubic and sacral region once a day for 4 weeks.
Number of subjects: 70
Study 29948596 — intervention group
Group type: COMPARATOR
Intervention: Almond placebo oil control group applied by self-massage on the suprapubic and sacral region once a day for 4 weeks.
Number of subjects: 70
Study 30275687 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week multicomponent intervention (group exercise, nutritional supplementation, depression management, deprescribing medications, home hazard reduction)
Number of subjects: 187
Study 30275687 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-week multicomponent intervention
Number of subjects: 187
Study 27627192 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1305 + ketoconazole
Number of subjects: 0
Study 27627192 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1305 + verapamil
Number of subjects: 0
Study 27627192 — intervention group
Group type: COMPARATOR
Intervention: AZD1305 alone
Number of subjects: 0
Study 24393349 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 1125
Study 24393349 — intervention group
Group type: COMPARATOR
Intervention: Sham or PDT
Number of subjects: 1125
Study 21343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat (2, 10, 20, 50, 100, 200, 400, 600, 900, or 1200 mg)
Number of subjects: 80
Study 21343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Etamicastat (100 mg and above)
Number of subjects: 80
Study 21343348 — intervention group
Group type: COMPARATOR
Intervention: Etamicastat
Number of subjects: 80
Study 21343348 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylated metabolite of etamicastat
Number of subjects: 80
Study 20339359 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction (BMI reduction by 1 SDS, n = 51; and 2 SDS, n = 21) under conservative treatment for 18 months.
Number of subjects: 70
Study 20339359 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained weight reduction for 6 months after initial weight loss.
Number of subjects: 70
Study 20339359 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group of healthy prepubertal children).
Number of subjects: 70
Study 22901116 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-professional Intervention and Training for Ongoing Volunteer-based Community Health Programme
Number of subjects: 2045
Study 15901395 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive, smaller gift items
Number of subjects: 0
Study 15901395 — intervention group
Group type: EXPERIMENTAL
Intervention: Less luxurious, more useful gifts
Number of subjects: 0
Study 15901395 — intervention group
Group type: EXPERIMENTAL
Intervention: Gift vouchers
Number of subjects: 0
Study 15901395 — intervention group
Group type: COMPARATOR
Intervention: Cash gifts
Number of subjects: 0
Study 15901395 — intervention group
Group type: EXPERIMENTAL
Intervention: Separate evaluations of gifts
Number of subjects: 0
Study 12358231 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy
Number of subjects: 67
Study 12358231 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 67
Study 12358231 — intervention group
Group type: COMPARATOR
Intervention: Patients with symptomatic gallstones
Number of subjects: 67
Study 10469705 — intervention group
Group type: EXPERIMENTAL
Intervention: Group culture in a small volume
Number of subjects: 0
Study 10469705 — intervention group
Group type: EXPERIMENTAL
Intervention: Single culture in a small volume
Number of subjects: 0
Study 10469705 — intervention group
Group type: EXPERIMENTAL
Intervention: Single culture in a large volume
Number of subjects: 0
Study 10469705 — intervention group
Group type: EXPERIMENTAL
Intervention: Group culture in a large volume
Number of subjects: 0
Study 10469705 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 8912492 — intervention group
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation (VNS)
Number of subjects: 100
Study 1744867 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg timolol orally
Number of subjects: 100
Study 1744867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 6750167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 683
Study 6750167 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 683
Study 30045259 — intervention group
Group type: COMPARATOR
Intervention: Melatonin (ML)
Number of subjects: 88
Study 30045259 — intervention group
Group type: COMPARATOR
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 88
Study 27334116 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations intervention (nine-session psychoeducational program)
Number of subjects: 399
Study 27334116 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations intervention
Number of subjects: 399
Study 27334116 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 399
Study 26162825 — intervention group
Group type: EXPERIMENTAL
Intervention: EVICEL™ applied during surgery (5 ml)
Number of subjects: 68
Study 26162825 — intervention group
Group type: COMPARATOR
Intervention: Electrocoagulation (standard treatment)
Number of subjects: 68
Study 23024015 — intervention group
Group type: COMPARATOR
Intervention: golimumab 100 mg
Number of subjects: 356
Study 23024015 — intervention group
Group type: COMPARATOR
Intervention: golimumab 50 mg
Number of subjects: 356
Study 20673353 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 322
Study 20673353 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (28 day cycles of cyclophosphamide, methotrexate and 5‐fluorouracil)
Number of subjects: 322
Study 20673353 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of radiotherapy and chemotherapy
Number of subjects: 322
Study 20673353 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific treatment mentioned)
Number of subjects: 322
Study 18486740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Number of subjects: 1230
Study 18486740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 1230
Study 18486740 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1230
Study 18486740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 8 weeks (for partial responders)
Number of subjects: 1230
Study 18486740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg every 12 weeks (for partial responders)
Number of subjects: 1230
Study 18486740 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg (for partial responders)
Number of subjects: 1230
Study 16901250 — intervention group
Group type: EXPERIMENTAL
Intervention: bio-psychosocial approach including virtual reality
Number of subjects: 211
Study 12531444 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (1 g IV at induction of anesthesia)
Number of subjects: 1013
Study 12531444 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (1 g IV at induction of anesthesia)
Number of subjects: 1013
Study 11064186 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg sublingual buprenorphine + 0 mg naloxone
Number of subjects: 9
Study 11064186 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg sublingual buprenorphine + 4 mg naloxone
Number of subjects: 9
Study 11064186 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg sublingual buprenorphine + 8 mg naloxone
Number of subjects: 9
Study 11064186 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous buprenorphine + naloxone
Number of subjects: 9
Study 11064186 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine bioavailability
Number of subjects: 9
Study 11064186 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone bioavailability
Number of subjects: 9
Study 8673309 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically applied recombinant human platelet‐derived growth factor (rhPDGF)
Number of subjects: 118
Study 8673309 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 118
Study 2052484 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.6 ml intranasal dose, 60 micrograms)
Number of subjects: 0
Study 2052484 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7101088 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefonicid (1 g, intramuscularly)
Number of subjects: 83
Study 7101088 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 x 10^6 units) plus probenecid (1.0 g)
Number of subjects: 83
Study 30209152 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TN-TC11M (THC 2.5mg/CBD 2.5mg) capsules
Number of subjects: 80
Study 30209152 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 80
Study 27871549 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural chloroprocaine 1.2% mixed with 0.4μg/mL fentanyl
Number of subjects: 120
Study 27871549 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural chloroprocaine (0.6%, 0.8%, 1.0%, 1.2%, 1.4%)
Number of subjects: 120
Study 25826885 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral tibiofemoral joint 90° flexional gap measurement resection
Number of subjects: 60
Study 25826885 — intervention group
Group type: COMPARATOR
Intervention: Traditional osteotomy (control group)
Number of subjects: 60
Study 22457736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep after learning
Number of subjects: 0
Study 22457736 — intervention group
Group type: COMPARATOR
Intervention: Wakefulness after learning
Number of subjects: 0
Study 22457736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep preceding wakefulness
Number of subjects: 0
Study 22457736 — intervention group
Group type: COMPARATOR
Intervention: 12 hr of waking interference
Number of subjects: 0
Study 22457736 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep at 24 hr retest
Number of subjects: 0
Study 20378307 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐incision modified Smith‐Peterson approach
Number of subjects: 100
Study 20378307 — intervention group
Group type: COMPARATOR
Intervention: Direct lateral approach
Number of subjects: 100
Study 20378307 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 18795916 — intervention group
Group type: EXPERIMENTAL
Intervention: V. filiformis cream 5%
Number of subjects: 75
Study 18795916 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream (placebo)
Number of subjects: 75
Study 16176175 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine+lamivudine treatment
Number of subjects: 232
Study 16176175 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine+stavudine treatment
Number of subjects: 232
Study 16176175 — intervention group
Group type: COMPARATOR
Intervention: Comparison between zidovudine+lamivudine and didanosine+stavudine
Number of subjects: 232
Study 12136395 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg once daily for 6 weeks)
Number of subjects: 20
Study 10447629 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic nail (intramedullary implant) for fixation of peritrochanteric fractures
Number of subjects: 85
Study 7493234 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.006%
Number of subjects: 20
Study 7493234 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 20
Study 1693762 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg and 10 mg of heroin
Number of subjects: 0
Study 1693762 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg and 2 mg of hydromorphone
Number of subjects: 0
Study 1693762 — intervention group
Group type: COMPARATOR
Intervention: Repeated doses of the same drug
Number of subjects: 0
Study 1693762 — intervention group
Group type: COMPARATOR
Intervention: Repeated doses of the alternate drug
Number of subjects: 0
Study 1693762 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (heroin and hydromorphone)
Number of subjects: 0
Study 1693762 — intervention group
Group type: EXPERIMENTAL
Intervention: Covariate analysis
Number of subjects: 0
Study 489201 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 40 mg orally
Number of subjects: 24
Study 489201 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 24
Study 489201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31977110 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers of preterm infants
Number of subjects: 547
Study 31977110 — intervention group
Group type: EXPERIMENTAL
Intervention: Fathers of preterm infants
Number of subjects: 547
Study 31977110 — intervention group
Group type: EXPERIMENTAL
Intervention: Very preterm infants' mothers
Number of subjects: 547
Study 31977110 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of twins
Number of subjects: 547
Study 31977110 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with lower perceived general health
Number of subjects: 547
Study 30359681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab 100 mg subcutaneously every 4 weeks plus standard of care
Number of subjects: 347
Study 30359681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 347
Study 28317287 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pharyngeal electrical stimulation (PES) at 5 Hz, 75% of maximal tolerated intensity, for 10 minutes once a day for three consecutive days.
Number of subjects: 38
Study 28317287 — intervention group
Group type: COMPARATOR
Intervention: Sham pharyngeal electrical stimulation (PES)
Number of subjects: 38
Study 23498594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCSs) treatment during acute LRTIs, n = 70
Number of subjects: 493
Study 23498594 — intervention group
Group type: COMPARATOR
Intervention: No treatment with OCSs during acute LRTIs, n = 42
Number of subjects: 493
Study 23498594 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral corticosteroids (OCSs) treatment during severe LRTIs, n = 133 (from the second cohort)
Number of subjects: 493
Study 21221987 — intervention group
Group type: EXPERIMENTAL
Intervention: Static hand grip test (HGT) at 30% of maximal voluntary contraction
Number of subjects: 45
Study 21221987 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT)
Number of subjects: 45